Merrimack Initiates Phase I MM-398 Trial

To evaluate cyclophosphamide combination in pediatric tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merrimack Pharmaceuticals has initiated a Phase I dose-escalating trial of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors. Preclinical research suggests MM-398 administration results in sustained delivery of larger quantities of chemotherapy as compared to conventional administration.   The Phase I study will assess the safety of M...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters